Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.
As part of the deal, Kinaxo will use its PhosphoScout phosphoproteomics technology to assess drugs under development at Takeda.
The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."
Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale.
Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work.
The Japanese drug firm will use Kinaxo's Cellular Target Profiling, KinAffinity, and PhosphoScout products.
Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.
The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.
Christian Jurinke, Jeff Protentis, Jürgen Schumacher
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.